| |
 |
|
Celebrates 10 Years of Leadership in Clinical Research for SCIREX Corporation
SCIREX Corporation, a leader in the delivery of drug development services
to the global pharmaceutical and biotechnology industries, this month celebrates
the 10th anniversary of its incorporation.
SCIREX Corporation, a leader in the delivery of drug development services to the global pharmaceutical and biotechnology industries, this month celebrates the 10th anniversary of its incorporation. In February1996, Biomedical Research Group and National Medical Research Corporation merged to form what is now known as SCIREX Corporation. Since that time, SCIREX has become the premier provider of clinical research services for Analgesia and Central Nervous System disorders.
In a message to the company marking the milestone, CEO James Utterback thanked employees for their contributions to the success of the enterprise and of its clients. “We go past our 10th Anniversary with many goals and opportunities ahead of us…I am proud to be a part of this company's history and future. You, too, should fill with pride when you consider how important each of your contributions are to improving health and bringing new medications to the global marketplace.”
SCIREX now helps clients address every phase of drug development process, including full Phase I-IV clinical research, early development services, and post-marketing solutions. Additionally, in 2005 SCIREX expanded operations farther into Europe with the opening of its Poland office and formed strategic partnerships with Clinigene/Biocon Ltd. in India and GleneaglesCRC in Singapore.
SCIREX now has offices in Philadelphia, Chicago, San Diego, Austin, Salt Lake City, Tampa, Hartford, London and Krakow. Its 450+ employees have conducted more than 1,000 studies involving more than 130,000 patients. Approximately 80% of its clients are drawn from emerging and mid-tier Pharma and long-term commercial implications necessitate a thoughtful, customized approach to your post-marketing clinical research. SCIREX integrates the scientific rigor and therapeutic and Biotech while the remainder includes some of the largest global pharmaceutical companies in the industry. Regardless of growth, Utterback observed that “therapeutic focus, scientific expertise, and quality will continue to guide our efforts.”
“Ultimately, the measure of our success,” added Utterback, “will be continuous improvement in each of Research and Medical Marketing Support
SCIREX helps you craft the study design and program support necessary for effective post-marketing clinical research, including:
• Registries
• Health Economic & Outcomes Research
• Quality of Life Studies
• Label Change
four key metrics: client satisfaction, employee satisfaction, project team performance, and financial performance. Moving forward, we will continue to practice a passionate focus on quality and client satisfaction, to bring our clients the best in class services they have come to expect from SCIREX.”
Up to 80% of new drug approvals require a post-marketing study as a condition of approval…[The FDA] is expected to include not only requests for more post-marketing studies as a condition of approval, but a crackdown on ensuring requested studies are done.”
|
|
|
|
